There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d6343984e70">The burden and impact of secondary superadded infections
in critically ill coronavirus
disease 2019 (COVID-19) patients is widely acknowledged. However, there is a dearth
of information regarding the impact of COVID-19 in patients with tuberculosis, HIV,
chronic hepatitis, and other concurrent infections. This review was conducted to evaluate
the consequence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection
in patients with concurrent co-infections based on the publications reported to date.
An extensive comprehensive screening was conducted using electronic databases up to
3rd September 2020 after obtaining registration with PROSPERO (CRD420202064800). The
observational studies or interventional studies in English, evaluating the impact
of SARS-CoV-2 in patients with concurrent infections are included for the meta-analyses.
Our search retrieved 20 studies, with a total of 205,702 patients. Patients with tuberculosis
(RR = 2.10; 95% CI, 1.75-2.51; I2 = 0%), influenza (RR = 2.04; 95% CI, 0.15-28.25,
I2 = 99%) have an increased risk of mortality during a co-infection with SARS-CoV-2.
No significant impact is found in people living with HIV (RR = 0.99; 95% CI, 0.82-1.19;
I2 = 30%), Chronic hepatitis (RR = 1.15; 95% CI, 0.73-1.81; I2 = 10%). Several countries
(Brazil, Paraguay, Argentina, Peru, Colombia, and Singapore) are on the verge of a
dengue co epidemic (cumulative 878,496 and 5,028,380 cases of dengue and COVID-19
respectively). The impact of COVID-19 in patients of concurrent infections with either
tuberculosis or influenza is detrimental. The clinical outcomes of COVID-19 in HIV
or chronic hepatitis patients are comparable to COVID-19 patients without these concurrent
infections.
</p>